Similar articles

• [Non-small cell lung cancer - from treatment of relapse to treatments for relapses].

  Souquet PJ. Souquet PJ. Rev Mal Respir. 2007 Oct;24(8 Pt 2):6S108-13. Rev Mal Respir. 2007. PMID: 18235402 Review. French.
• [Second-line chemotherapy in non-small-cell lung cancer].

  Schütte W. Schütte W. Rev Pneumol Clin. 2004 Nov;60(5 Pt 3):4S13-4S16. Rev Pneumol Clin. 2004. PMID: 15687987 Review. French. No abstract available.
• Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

  O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T. O'Brien ME, et al. J Clin Oncol. 2006 Dec 1;24(34):5441-7. doi: 10.1200/JCO.2006.06.5821. J Clin Oncol. 2006. PMID: 17135646 Clinical Trial.
• Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.

  Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G. Eckardt JR, et al. J Clin Oncol. 2007 May 20;25(15):2086-92. doi: 10.1200/JCO.2006.08.3998. J Clin Oncol. 2007. PMID: 17513814 Clinical Trial.
• New advances in the second-line treatment of small cell lung cancer.

  Hurwitz JL, McCoy F, Scullin P, Fennell DA. Hurwitz JL, et al. Oncologist. 2009 Oct;14(10):986-94. doi: 10.1634/theoncologist.2009-0026. Epub 2009 Oct 9. Oncologist. 2009. PMID: 19819917 Review.